Overview

Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
Patients who have been treated in study protocol BAP089 may have responded to treatment, and subsequently relapsed to >75% of the baseline disease severity, will be investigated for response to further treatment with alitretinoin. Also, patients who have responded with mild or moderate disease will be investigated for additional treatment effect after prolongated treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Basilea Pharmaceutica
Treatments:
Alitretinoin
Tretinoin